M&A
Gilead to Acquire Forty Seven for $4.9 Billion
Gilead Sciences
PR-M03-20-NI-003Mar 02, 2020
Strategic Collaboration
Forty Seven Inc. to Collaborate on a Novel Immuno-Oncology Combination for Leukemia and Bladder Cancer
Forty Seven Inc.
PR-M01-18-NI-043Jan 16, 2018
Immuno-Oncology
Forty Seven Inc. to Collaborate with Merck KGaA, Darmstadt, Germany, on a Novel Immuno-Oncology Combination for Ovarian Cancer
Forty Seven Inc.
PR-M01-18-NI-042Jan 16, 2018